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ABSTRACT
Introduction: A new treatment plan was
implemented at Ska˚ne University Hospital, on
economic grounds, for children requiring
recombinant human growth hormone (rhGH)
treatment. This involved switching patients
from treatment with originator rhGHs to
treatment with a biosimilar rhGH, somatropin
(Omnitrope), using a Dialogue Teamwork
approach. The feasibility of using this
approach to implement the switch of
treatment was assessed, as well as the impact
of the switch on treatment efficacy and cost of
therapy.
Methods: As part of the Dialogue Teamwork
approach, patients/parents received several
opportunities for dialogue and sources of
information, including discussions with the
Head of Department, the responsible physician
and a specialized endocrinology nurse. Height
and height standard deviation score (HSDS)
data were plotted for each individual patient
(N = 98). A modeling approach was also used, to
predict growth after switching to biosimilar
rhGH; the predictions were then compared to
the actual observed height after the switch.
Costs to the clinic of rhGH therapy were
calculated between May–August 2009 and
May–August 2012.
Results: Of the 102 patients offered the switch,
98 accepted. Height and HSDS data indicated
there was no negative impact on growth
velocity after the switch to biosimilar rhGH.
Modeling demonstrated that observed growth
following the switch was consistent with
predicted growth based on data before patients
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were switched. There were no reports of serious
or unexpected adverse drug reactions following
the switch to biosimilar rhGH. Following the
switch, the cost to the clinic of rhGH treatment
decreased from approximately 6 million SEK
(May–August 2009) to approximately 4 million
SEK (May–August 2012). This corresponds to an
annual saving of 6 million SEK (€650,000).
Conclusion: Patients were successfully
switched from originator to biosimilar rhGH
(somatropin), with no negative impact on
growth, and no serious or unexpected adverse
drug reactions. The switch from originator to
biosimilar rhGH is associated with substantial
cost savings.
Keywords: Biosimilar; Cost savings; Growth
disturbances; Human growth hormone;
Omnitrope; Pediatric; Switch
INTRODUCTION
Without intervention, even wealthy countries
face a crisis in healthcare spending; escalating
costs are driven, at least in part, by novel,
high-cost biopharmaceuticals [1]. Sales of
biopharmaceuticals currently amount to
almost $70 billion in the US, and €60 billion
in Europe [2, 3]. The expiration of patents for
biopharmaceuticals allows pharmaceutical
companies to develop and produce similar
biological medicinal products, also known as
biosimilars. The European Medicines Agency
(EMA) defines biosimilars as medicines that are
similar to a biological medicine that has already
been approved [4]. ‘Biosimilar’ is therefore a
regulatory term used to indicate a
biopharmaceutical product that has been
approved under a well-defined regulatory
pathway. The principal reason for using
biosimilar drugs is for cost saving [1]; the
uptake of biosimilars will therefore depend on
the degree to which cost savings are required by
healthcare systems and the absolute savings
that could be gained by switching from original
drugs.
A number of recombinant human growth
hormone (rhGH) products are available for the
treatment of pediatric growth disturbances,
including somatropin (Omnitrope, Sandoz,
Kundl, Austria). Omnitrope is a rhGH
approved by the EMA in 2006; approval was
granted via the biosimilar regulatory pathway,
on the basis of comparable quality, safety, and
efficacy to the reference product (Genotropin,
Pfizer, Sollentuna, Sweden) [5]. Omnitrope is
also approved in other territories including
Australia, Canada, the Middle East, the Far East
(e.g., Japan, Taiwan), Central and South America
(e.g., Mexico, Argentina, Brazil), and has received
positive opinion from the UK’s National Institute
for Health and Clinical Excellence (NICE) [6]. In
addition, the product is approved for use in the
United States (US); due to the lack of a formal
biosimilar regulatory pathway, Omnitrope was
approved in the US following a New Drug
Application via the pathway described by
Section 505(b)2 of the Federal Food, Drug, and
Cosmetic Act. Omnitrope is licensed for use to
treat growth disturbances in the following
pediatric indications; growth hormone
deficiency (GHD), Turner Syndrome, chronic
renal insufficiency, children born small for
gestational age, and Prader–Willi Syndrome [7].
It is also approved for the treatment of adult GHD
and, in the US, idiopathic short stature.
The availability of biosimilar medicines has
potentially substantial benefits for healthcare
providers and patients in terms of reducing drug
expenditure and possibly increasing patient
access to treatments [8]. In Sweden, almost all
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health care is publicly funded via taxes, and there
is pressure to contain healthcare expenditure.
Ska˚ne University Hospital (Malmoe, Sweden) is
responsible medically and financially for the
prescription of rhGH treatment to children at
six hospitals in the Ska˚ne region. In June 2009, a
new treatment plan was implemented, on
economic grounds, for children requiring rhGH
treatment. This involved switching patients from
existing treatment with originator rhGHs to
treatment with biosimilar rhGH (Omnitrope),
using a Dialogue Teamwork approach. Dialogue
Teamwork can be used to implement changes in
health care without adopting a top-down
approach, and its main component is
interprofessional education [9]. This
manuscript describes the implementation of
this new treatment plan, and its impact in
terms of treatment efficacy, safety, and cost
savings.
METHODS
Implementation of the Switch
to Biosimilar rhGH
A total of 120 patients were considered for a
switch to treatment with biosimilar rhGH; 102
were finally offered a switch using a Dialogue
Teamwork approach. Patients not offered the
switch had an expected duration of further
rhGH treatment \6 months (n = 16), or a
history of allergic reaction to other growth
hormone preparations (n = 2). All patients (or
their parents) offered the switch were provided
with the following information or support to
aid their decision as part of the Dialogue
Teamwork approach:
• a letter from the Head of Department of
Pediatrics explaining the economic rationale
for the switch;
• the opportunity to discuss the medical
aspects of the switch with the physician
responsible for patient care;
• further dialogue with the Head of
Department if patients did not accept the
switch after the discussion with the
responsible physician;
• information on the biosimilar rhGH
(somatropin) from the EMA;
• a visit to a specialized endocrinology nurse
to receive instructions on how to perform
the switch (e.g., use the new device) and to
ask any questions concerning the switch;
• the telephone number of the specialized
endocrinology nurse to contact for advice.
The patients were familiar with the physician
responsible for patient care and the specialized
endocrinology nurse, the team that started the
previous treatment with rhGH. Patients who
still did not accept the switch were offered the
opportunity to continue with the originator
product by contributing the difference in cost of
treatment between the originator and
biosimilar rhGH. All treatments, visits, tests,
and assessments were performed as part of
routine clinical practice; no additional or
specific visits, tests, or assessments were
required as part of the study (except for the
additional visit to the specialized nurse for
patients/carers to receive instructions on use
of the new device).
Ethics Approval
In Sweden, approval from an ethics committee
is not required if the following criteria apply:
the work involved is essentially a check on the
quality of the clinical work in a hospital; the
data analyzed is collected as part of the normal
clinical management of patients; and the data
collected are analyzed anonymously. The work
fulfilled all three of these criteria. The findings
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reported here were obtained as part of the
normal clinical management of the patients,
which was conducted in accordance with the
Declaration of Helsinki and the International
Conference on Harmonisation Good Clinical
Practice. All patients (or their parents)
consented verbally to the change in clinical
management, from treatment with originator
rhGH to treatment with a biosimilar rhGH,
following provision of relevant information and
discussions with the clinical team. This verbal
consent was documented in the hospital
records. Patients/parents were informed that
the change of treatment was to be monitored
by assessment of their growth data.
Efficacy Assessments and Modeling
Approach
Height and height standard deviation score
(HSDS) data were plotted for each individual
patient. In addition, a modeling approach
was used for the statistical assessment of
switchability to biosimilar rhGH. A logarithmic
model for height had already been developed
[10]. This model was used to fit the growth data
before switching to biosimilar rhGH. More
precisely, the fitted model was as follows:
hij ¼ a0 þ a0i þ a1 age0i  9:6
 
þ a2 þ a2ið Þ log 1 þ 12tij=30
  þ eij
where hij is the height measured on child i and
occasion j, tij is the time from first visit in years,
age0i is the initial age, the as are fixed-effect
parameters, the as and e are random (normal)
terms.
This model was used to predict the
individual growth trajectories after switching
to biosimilar rhGH treatment; the predictions
were then compared to the actual observed
height after the switch to biosimilar rhGH.
RESULTS
Of the 102 patients who were offered the switch
to biosimilar rhGH, 98 decided to accept. Five
patients took up the option of further dialogue
with the Head of Department. No patient took
up the option of remaining on originator rhGH
by contributing to the cost of therapy. The
remaining four patients were allowed to
continue with their original treatment,
without contributing to the cost of therapy,
by special arrangement with the Head of
Department; the reasons for these
arrangements were lifestyle considerations in
two cases and psychological considerations in
the other two cases. Characteristics of the
patients who accepted the switch are shown in
Table 1; the primary growth disturbance among
these patients was GHD (n = 40; 41%). Six
patients who switched to biosimilar rhGH
reverted to their originator treatment; for
three of these patients no height
measurements are available for the period they
were receiving biosimilar rhGH.
Height and HSDS data indicate no impact on
growth velocity after patients were switched to
treatment with biosimilar rhGH (Fig. 1).
Similarly, analysis of height data suggests no
Table 1 Patient characteristics
Patients who agreed to switch (n) 98
Male/female (n) 52/46
Age range (years) 1–15




Small for gestational age 11
Other 36
a Four patients had dual diagnosis
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impact of the switch in each of the different
growth disturbances (Fig. 2). The modeling
approach described earlier was used to predict
individual growth trajectories after switching
treatments (Fig. 3). The model was then used to
compare the observed and predicted growth
following the switch to biosimilar rhGH (Fig. 4);
all data points lie close to the identity line
(R2 = 0.992, calculated between the predicted
and observed values), demonstrating that the
observed growth following the switch was
consistent with predicted growth based on data
before patients were switched. The standard
deviation of differences between predicted and
observed values was 1.9 cm; that is, 90% of the
predicted values are expected to lie within 3 cm
of the values actually observed (assuming
normal distribution of the differences).
There were no reports of serious or
unexpected adverse drug reactions (ADRs)
following the switch to biosimilar rhGH. A
total of 19 ADRs (in 18 patients) were reported
in the 12 months following the switch; 18
patients experienced pain at injection site
(6 patients switched back to their originator
rhGH preparation, 12 initially reported pain on
injection but continued with biosimilar
treatment following provision of advice and
education on injection technique by a
specialized endocrinology nurse), and one
patient also experienced pitting edema. Of the
12 patients who experienced injection-site pain
but continued with biosimilar treatment, 3
required an extra visit to the responsible
physician or specialized nurse, and 10 required
extra phone contact with the physician/nurse.
In the period May to August 2009, the cost to
the clinic of rhGH therapy was approximately 6
million SEK; by the period May to August 2012,
the cost to the clinic of rhGH had decreased to
approximately 4 million SEK (Fig. 5). This
provides an annual saving of 6 million SEK
(€650,000).
DISCUSSION
This study indicates that Dialogue Teamwork can
be successfully used to implement a switch from
originator to biosimilar rhGH in children with
growth disturbances. The switch to biosimilar
rhGH had no impact on the children’s growth
and at the same time provided substantial cost
Fig. 1 Growth data before and after switching to biosimilar
recombinant human growth hormone. a Height by time
from ﬁrst visit; b height standard deviation score (SDS) by
time from ﬁrst visit. Open circle originator rhGH, ﬁlled
circle biosimilar rhGH
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savings. No serious or unexpected ADRs were
reported following the switch to biosimilar
rhGH. As expected, injection-site pain was the
most commonly reported ADR. The number of
patients reporting this ADR may be explained, at
least in part, by the fact that switching to a
different rhGH product also involves the use of a
new injection device. Consequently, patients
must learn, and get used to, a different
injection technique. Reinforcing this point,
most patients who reported injection-site pain
initially were able to continue with their
treatment following advice on injection
technique from an endocrine nurse.
The incentive for implementing the switch
from originator to biosimilar rhGH was financial,
and all money saved was retained by the clinic to
spend elsewhere rather than being put back into
the regional healthcare budget. An important
factor in implementing the switch was ensuring
patient adherence to therapy. Interventions to
improve medical adherence typically focus on
the motivation or attitudes of the individual
patient or family [11]. However, a systematic
review concluded that these approaches result in
only modest improvements [12]. The interaction
between the patient/family and the team of
healthcare professionals was assessed using
systematic techniques in order to identify and
remove potential barriers to the switch from
originator to biosimilar rhGH [13–15]. The focus
of this study was then to change, through
Fig. 2 Height data before and after switching to biosimilar
recombinant human growth hormone in patients with
different growth disturbances a Prader–Willi syndrome,
b growth hormone deﬁciency, c Turner syndrome, d born
small for gestational age, e other. Open circle originator
rhGH, ﬁlled circle biosimilar rhGH
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interprofessional education [9], the way the
healthcare professionals collaborated in order
to facilitate the patient/family in adapting to the
switch.
Previous attempts in Sweden to enforce a
similar treatment switch have failed, largely
because of protests from patients and their
families that resulted in unfavorable media
coverage. The Dialogue Teamwork approach
employed enables changes in health care to be
implemented through dialogue with, and
involvement of, the patient/family and without
the need for top-down mandates. Based on this
study it is hypothesized that there are four critical
elements to the success of such an approach in
driving a change in the interactions between
health professionals: (1) providing patients with
clear information about the reasons for the
change; (2) allowing individual patients/carers
sufficient opportunities to discuss the change
with the different healthcare professionals
involved; (3) a joint team approach that avoids
mixed messages from the different healthcare
professionals involved; (4) providing patients
with the reassurance of personal support
throughout the change.
There is little published information on the
impact of switching between GH products.
Fig. 3 Illustration of the modeling approach to predict
growth trajectories after switch to biosimilar recombinant
human growth hormone (rhGH). The ﬁgure illustrates
growth trajectories for nine sample patients. The model was
ﬁtted to originator rhGH and used to predict growth
trajectories after switch to biosimilar rhGH. The solid lines
represent the predicted growth trajectory of each individual.
The dashed line represents the predicted growth trajectory
of the typical individual in the dataset. Open circle
originator rhGH, ﬁlled circle biosimilar rhGH
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Studies that are available have concentrated on
switching between originator products, and
assessed physician attitudes or the potential
additional administration burden on clinics
[16, 17]. In another study, using data from
clinical trials, it was concluded that switching
from originator to biosimilar rhGH had no
impact on the efficacy and safety of treatment
in children with GHD [10]. The data are
consistent with, and extend those, from this
previous study; ours is the first study to
demonstrate no impact on growth trajectory
when switching rhGH products in real-life
clinical practice.
This study indicates the substantial savings
that can be achieved by switching from originator
to biosimilar rhGH, with costs to the clinic of
rhGH therapy decreasing by approximately
one-third between the periods May–August 2009
and May–August 2012. It is possible that these
data underestimate the savings that are available
by switching to biosimilar rhGH, since the overall
cost of therapy also includes patients who
switched back to originator rhGH. Data from the
University College London Hospitals NHS Trust
also indicate the substantial cost savings possible
when switching all patients in a single center from
originator rhGH to biosimilar rhGH, with annual
savings estimated as in excess of £200,000 [18].
CONCLUSION
Dialogue Teamwork can be used to successfully
switch patients from originator to biosimilar
rhGH therapy (somatropin), with no negative
impact on the patients’ growth, and no serious
or unexpected ADRs. This strategy is associated
with substantial cost savings.
ACKNOWLEDGMENTS
The authors would like to thank Dr Johan
Svensson and Carina Persson for their
contribution to implementing the new treatment
plan. Medical writing assistance in the preparation
of this paper was provided by Tony Reardon of
Spirit Medical Communications Ltd, and funded
by Sandoz International GmbH. Article
publication charges were also funded by Sandoz
Fig. 4 Assessment of observed versus predicted height
following the switch to recombinant human growth
hormone. The solid line is the identity line (i.e., points
lying on this line have the same predicted and observed
values of height)
Fig. 5 Costs to the clinic of growth hormone therapy
following the switch from originator to biosimilar
recombinant human growth hormone (switch occurred
in T2 2009)
42 Biol Ther (2013) 3:35–43
123
International GmBH. Dr. C.-E. Flodmark is the
guarantor for this article, and takes responsibility
for the integrity of the work as a whole.
Conflict of interest. Carl-Erik Flodmark has
acted as a consultant to Sandoz, but received no
financial reimbursement for conducting this
work described in this paper. Heike Woehling
is an employee of HEXAL AG/Sandoz. Katarina
Lilja and Kajsa Ja¨rvholm have declared no
conflicts of interest.
Compliance with ethical guidelines. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000. Informed consent was obtained from all
patients for being included in the study.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Cornes P. The economic pressures for biosimilar
drug use in cancer medicine. Target Oncol.
2012;7:S57–67.
2. Hirsch BR, Lyman GH. Biosimilars: are they ready
for primetime in the United States? J Natl Compr
Canc Netw. 2011;9:934–42.
3. Covic A, Cannata-Andia J, Cancarini G, et al.
Biosimilars and biopharmaceuticals: what the
nephrologists need to know—a position paper by
the ERA-EDTA Council. Nephrol Dial Transplant.
2008;23:3731–7.
4. Roger SD. Biosimilars: current status and future
directions. Expert Opin Biol Ther. 2010;10:1011–8.
5. Omnitrope European Public Assessment Report
2008. Available at: www.ema.europa.eu/docs/en_
GB/document_library/EPAR_-_Scientific_Discussion/
human/000607/WC500043692.pdf. Accessed 3 Nov
2011.
6. UK National Institute for Health and Clinical
Excellence. Human growth hormone (somatropin)
for the treatment of growth failure in children. May
2010. Available at: www.nice.org.uk/nicemedia/
live/12992/48715/48715.pdf. Accessed 2 Oct 2012.
7. Omnitrope Summary of Product Characteristics
2008. Available at: www.ema.europa.eu/docs/en_
GB/document_library/EPAR_-_Product_Information/
human/000607/WC500043695.pdf. Accessed 3 Nov
2011.
8. Aapro M, Cornes P. Biosimilars in oncology:
emerging and future benefits. GaBI J. 2013 (in press).
9. Reeves S, Tassone M, Parker K, Wagner SJ, Simmons
B. Interprofessional education: an overview of key
developments in the past three decades. Work.
2012;41:233–45.
10. Romer T, Zabransky M, Walczak M, Szalecki M,
Balser S. Effect of switching recombinant human
growth hormone: comparative analysis of phase 3
clinical data. Biol Ther. 2011;1:005.
11. Russell CL, Ruppar TM, Matteson M. Improving
medication adherence: moving from intention and
motivation to a personal systems approach. Nurs
Clin N Am. 2011;46:271–81.
12. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X.
Interventions for enhancing medication adherence.
Cochrane Database Syst Rev. 2008; CD000011.
13. NowickaP,FlodmarkCE.Family therapyasamodel for
treating childhood obesity: useful tools for clinicians.
Clin Child Psychol Psychiatry. 2011;16:129–45.
14. de Shazer S. Keys to solution in brief therapy. New
York: Norton; 1985.
15. Minuchin S, Fishman C. Family therapy techniques.
1st ed. Cambridge: Harvard University; 1981.
16. Nelson WW, Frear RS. Physician attitudes toward
human growth hormone products. Am J Health
Syst Pharm. 1999;56:51–6.
17. Grimberg A, Feudtner C, Gordon CM.
Consequences of brand switches during the course
of pediatric growth hormone treatment. Endo
Pract. 2012;18:307–16.
18. Thakrar K, Bodalia P, Grosso A. Assessing the
efficacy and safety of Omnitrope. Br J Clin Pharm.
2010;2:298–301.
Biol Ther (2013) 3:35–43 43
123
